Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: Systematic review and meta-analysis

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Cooper, Katy L ^a   Madan, Jason ^b   Whyte, Sophie ^a   Stevenson, Matt D ^a   Akehurst, Ron L ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IFOSFAMIDE; IRINOTECAN; MESNA; METHOTREXATE; METHYLPREDNISOLONE; OXALIPLATIN; PREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; DRUG EFFICACY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; GERM CELL TUMOR; HUMAN; INCIDENCE; LUNG SMALL CELL CANCER; LYMPHOMA; META ANALYSIS; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIMARY PREVENTION; RISK ASSESSMENT; RISK MANAGEMENT; SOFT TISSUE SARCOMA; SOLID TUMOR; SYSTEMATIC REVIEW; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; NEUTROPENIA; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; NEUTROPENIA; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 80053173427     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-404     Document Type: Article

References (39)

1. Kuderer N, Dale D, Crawford J, Cosler L, Lyman G. Mortality, Morbidity, and Cost Associated with Febrile Neutropenia in Adult Cancer Patients. CANCER 2006, 106:2258-2266. 10.1002/cncr.21847, 16575919.
2. Brown R, Hutton J, Burrell A. Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UK. Pharmacoeconomics 2001, 19:1091-1102. 10.2165/00019053-200119110-00003, 11735676.
3. Brown RE, Hutton J. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anticancer Drugs 1998, 9:899-907. 10.1097/00001813-199811000-00009, 9890701.
4. Shayne M, Crawford J, Dale D, Culakova E, Lyman G, . for the ANC Study Group Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 2006, 100:255-262. 10.1007/s10549-006-9254-4, 16705366, for the ANC Study Group.
5. Bonadonna G, Moliterni A, Zambetti M, Daidone M, Pilotti S, Gianni L, et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005, 330:217-222. 10.1136/bmj.38314.622095.8F, 546063, 15649903.
6. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996, 88:1907-1929.
7. Green M, Koelbl H, Baselga J, GAlid A, Guillem V, Gascon P, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Annals of Oncology 2003, 14:29-35. 10.1093/annonc/mdg019, 12488289.
8. Holmes F, O'Shaughnessy J, Vukelja S, Jones S, Shogan J, Savin M, et al. Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer. JOURNAL OF CLINICAL ONCOLOGY 2002, 20:727-731. 10.1200/JCO.20.3.727, 11821454.
9. Chevallier B, Chollet P, Merrouche Y, Roche H, Fumoleau P, Kerbrat P, et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995, 13:1564-1571.
10. Bui BN, Chevallier B, Chevreau C, Krakowski I, Peny AM, Thyss A, et al. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol 1995, 13:2629-2636.
11. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 2004, 10:1235-1244. 10.2174/1381612043452613, 15078138.
12. Molineux G. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anticancer Drugs 2003, 14:259-264. 10.1097/00001813-200304000-00002, 12679729.
13. Aapro MS, Bohlius J, Cameron DA, Dal LL, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011, 47:8-32.
14. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-3205. 10.1200/JCO.2006.06.4451, 16682719.
15. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Myeloid Growth Factors. 2011, 1-5-2010, National Comprehensive Cancer Network (NCCN).
16. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151:264-269.
17. PRISMA statement website. 2009, http://www.prisma-statement.org
18. Kuderer N, Dale D, Crawford J, Lyman G. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. JOURNAL OF CLINICAL ONCOLOGY 2007, 25:3158-6731. 10.1200/JCO.2006.08.8823, 17634496.
19. Pinto L, Liu Z, Doan Q. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2007, 23:2283-2295. 10.1185/030079907X219599, 17697451.
20. Higgins JPT, Green S. The Cochrane Collaboration Cochrane Handbook for Systematic Reviews of Interventions 2009, The Cochrane Collaboration.
21. Vogel C, Wojtukiewicz M, Carroll R, Tjulandin S, Barajas-Figueroa L, Wiens B, et al. First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study. J Clin Oncol 2005, 23:1178-1184. 10.1200/JCO.2005.09.102, 15718314.
22. Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 2007, 12:1416-1424. 10.1634/theoncologist.12-12-1416, 18165618.
23. Romieu G, Clemens M, Mahlberg R. Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: A randomized phase 2 trial. Critical Reviews in Oncology/Hematology 2007, 64:64-72. 10.1016/j.critrevonc.2006.12.007, 17317205.
24. Hecht JR, Pillai M, Gollard R, Dreiling L, Mo M, Malik I. Pegfilgrastim in colorectal cancer (CRC) patients (pts) receiving every-two-week (Q2W) chemotherapy (CT): Long-term results from a phase II, randomized, controlled study. JOURNAL OF CLINICAL ONCOLOGY 2009, 27:Abstract 4072.
25. Doorduijn JK, van der HB, van Imhoff GW, van der Hem KG, Kramer MH, van Oers MH, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003, 21:3041-3050. 10.1200/JCO.2003.01.076, 12915593.
26. Osby E, Hagberg H, Kvaloy S, Teerenhovi L, Anderson H, Cavallin-Stahl E, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003, 101:3840-3848. 10.1182/blood-2002-10-3238, 12531794.
27. Zinzani PL, Pavone E, Storti S, Moretti L, Fattori PP, Guardigni L, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997, 89:3974-3979.
28. Pettengell R, Gurney H, Radford J, Deakin D. Granulocyte Colony-Stimulating Factor to Prevent Dose-Limiting Neutropenia in Non-Hodgkin's Lymphoma: A Randomized Controlled Trial. Blood 1992, 80:1430-1436.
29. Timmer-Bonte J, de Boo T, Smit H, Biesma B, Wilschut F, Cheragwandi S, et al. Prevention of Chemotherapy-Induced Febrile Neutropenia by Prophylactic Antibiotics Plus or Minus Granulocyte Colony-Stimulating Factor in Small-Cell Lung Cancer: A Dutch Randomized Phase III Study. J Clin Oncol 2005, 23:7974-7984. 10.1200/JCO.2004.00.7955, 16258098.
30. Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. European Journal of Cancer 1993, 29:319-324.
31. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991, 325:164-170. 10.1056/NEJM199107183250305, 1711156.
32. Fossa SD, Kaye SB, Mead GM, Cullen M, de WR, Bodrogi I, et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998, 16:716-724.
33. del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer 2008, 8:332. 10.1186/1471-2407-8-332, 2628928, 19014494.
34. Gisselbrecht C, Haioun C, Lepage E, Bastion Y, Tilly H, Bosly A, et al. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. Leuk Lymphoma 1997, 25:289-300.
35. Gebbia V, Valenza R, Testa A, Cannata G, Borsellino N, Gebbia N. A prospective randomized trial of thymopentin versus granulocyte--colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy. Anticancer Res 1994, 14:731-734.
36. Gebbia V, Testa A, Valenza R, Borsellino N, Cipolla C, Cannata G, et al. A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma. J Chemother 1993, 5:186-190.
37. Holmes F, Jones S, O'Shaughnessy J, Vukelja S, George T, Savin M, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Annals of Oncology 2002, 13:903-909. 10.1093/annonc/mdf130, 12123336.
38. Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R, et al. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003, 44:1503-1508. 10.1080/1042819031000103953, 14565651.
39. Vose J, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, et al. Randomized, Multicenter, Open-Label Study of Pegfilgrastim Compared With Daily Filgrastim After Chemotherapy for Lymphoma. JOURNAL OF CLINICAL ONCOLOGY 2003, 21:514-519. 10.1200/JCO.2003.03.040, 12560443.